Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PTGES | O14684 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 2/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280847 | 0.96 | S1PR1 (0.59) | S1PR1PSEN1ALOX5PPARGPTGES | |
| SCHEMBL12337602 | 0.87 | S1PR1 (0.71) | S1PR1RXRARXRBRXRGTHRA | |
| SCHEMBL93004 | 0.84 | S1PR1 (0.55) | S1PR1PSEN1ALOX5PPARGPTGES | |
| SCHEMBL79227 | 0.81 | S1PR1 (0.70) | S1PR1 | |
| SCHEMBL79226 | 0.81 | S1PR1 (0.70) | S1PR1 | |
| SCHEMBL79510 | 0.81 | S1PR1 (0.70) | S1PR1 | |
| SCHEMBL15473186 | 0.81 | PTGDR2 (0.52) | S1PR1ALOX5PPARGPTGESPPARD | |
| SCHEMBL79315 | 0.81 | S1PR1 (0.60) | S1PR1PSEN1ALOX5PPARGPTGES | |
| SCHEMBL79242 | 0.81 | S1PR1 (0.60) | S1PR1PSEN1ALOX5PPARGPTGES | |
| SCHEMBL79241 | 0.81 | S1PR1 (0.60) | S1PR1PSEN1ALOX5PPARGPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | S1PR1 511/4885PSEN1 4747/4885ALOX5 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.